Clinical Trial

Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations. The main questions it aims to answer are: * Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients? * How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations. Participants will: \- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.
Trial Details
NCT Number NCT07604103
Lead Sponsor University of Brawijaya
Conditions Acute Coronary Syndromes (ACS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease)
Enrollment 60 participants
Start Date 2026-01-01
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-10-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-22